Loading…
Swiss maker of isolators and barrier/containment systems used in sterile pharmaceutical manufacturing.
Swiss maker of isolators and barrier/containment systems used in sterile pharmaceutical manufacturing.
Earns mainly from project orders for custom isolators (sealed chambers that keep sterile drug filling free of contamination), with delivery spread over months, and adds recurring revenue from qualification, spare parts and service on installed units. Order intake follows pharma and biotech capacity building.
In one line: A niche Swiss equivalent of Syntegon for isolators.
Moat: narrow (customer qualification, process know-how, regulatory licence). Validated equipment inside regulated sterile lines is costly to requalify.
Headquarters: Allschwil, Switzerland · Employees: 1,755
Size SKAN (SKAN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $1.92B, the 95th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 69.70 on 6 Nov 2026.
Performance Over six months the shares gained 49.4%, against -4.5% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 9.4% over the last twelve months (peer median +14.6%); the operating margin is 10.7% (peer median 11.5%).
Valuation It trades at 49.8× forward earnings against a peer median of 26.9× (5th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 12.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 363M | CHF 333M | CHF 361M | CHF 320M | CHF 277M |
| Revenue growth | — | -8% | +13% | +16% | — |
| Gross profit | CHF 265M | CHF 243M | CHF 253M | CHF 228M | CHF 190M |
| EBITDA | CHF 52.9M | CHF 38.6M | CHF 57.0M | CHF 50.1M | CHF 40.2M |
| Net income | CHF 30.0M | CHF 16.3M | CHF 38.8M | CHF 26.3M | CHF 19.0M |
| Free cash flow | CHF 21.5M | CHF 21.0M | -CHF 4.33M | -CHF 24.9M | CHF 35.4M |
| Capital expenditure | CHF 38.1M | CHF 45.9M | CHF 53.8M | CHF 35.3M | CHF 28.9M |
| Total debt | n/a | CHF 131M | CHF 10.6M | CHF 6.49M | CHF 23.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SKAN SKAN.SW | $1.92B | +49% | +9% | 11% | 49.8× | 13.8% |
| Getinge GETI-B.ST | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SKAN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | +0.3% | 10th lowest of 21 |
| 6-month return | +49.4% | -4.5% | 2nd highest of 21 |
| Distance from 52-week high | -9.9% | -31.4% | 4th highest of 21 |
| Revenue growth (TTM) | +9.4% | +14.6% | 8th lowest of 21 |
| Operating margin | 10.7% | 11.5% | 10th lowest of 21 |
| Forward P/E | 49.8× | 26.9× | 5th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 13.8% | 11.4% | 6th most demanding of 15 |
| Growth delivered (Del g) | +11.7% | +11.5% | 8th highest of 15 |
| Hurdle (Req g minus delivered) | +2.1 pp | -9.1 pp | 5th most demanding of 15 |
| ROIC minus cost of capital | +12.5 pp | -1.3 pp | 4th highest of 21 |
| EV / EBITDA | 30.6× | 13.7× | 4th most expensive of 12 |
| Net debt / EBITDA | 0.8× | -1.2× | 4th most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SKAN SKAN.SW | Switzerland | $1.92B | +49% | +9% | 11% | 49.8× | 13.8% | +11.7% |
| Veracyte VCYT | United States | $1.94B | -40% | +17% | 17% | 14.9× | 15.1% | +34.5% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $1.89B | +17% | +5% | 7% | 9.4× | -12.6% | +0.4% |
| Mehow Innovative 301363.SZ | China | $1.95B | -14% | +10% | 21% | 38.8× | 18.9% | +12.9% |
| DENTSPLY SIRONA XRAY | United States | $1.89B | -14% | -1% | 5% | 7.3× | 10.2% | +1.9% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.96B | -4% | +7% | 14% | 8.8× | -11.8% | +2.1% |
| JEOL 6951.T | Japan | $1.98B | -3% | -18% | 11% | 14.2× | 21.3% | +10.2% |
| Inspire Medical Systems INSP | United States | $1.85B | +45% | 0% | 2% | 45.4× | 30.9% | +51.2% |
| LeMaitre Vascular LMAT | United States | $1.85B | -25% | +12% | 29% | 26.2× | 2.9% | +14.0% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.85B | -5% | +11% | 25% | 53.2× | 6.6% | +14.6% |
| Establishment Labs ESTA | United States | $2.00B | -7% | +38% | -7% | n/a | n/a | n/a |
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 74.2× | n/a | n/a |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 40.7× | n/a | n/a |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Bonesupport BONEX.ST | Sweden | $2.16B | +34% | +25% | 25% | 61.9× | 13.3% | +45.4% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |